Trials / Completed
CompletedNCT00027027
Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors
A Phase I, Open-Label, Multicenter, Dose-Escalation Study of the Safety and Pharmacokinetics of a Recombinant Humanized Antibody to Her2 (rhuMAb 2C4) Administered Every 3 Weeks to Subjects With Advanced Solid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this Phase I study is to test the safety of rhuMAb 2C4 to see what effects (good and bad) it has on patients with certain types of cancer, and also to find the highest dose of rhuMAb that can be given without causing severe side effects. All study participants will be assigned to specific group to evaluate different dosages of rhuMAb 2C4. The study is scheduled to run for up to one year depending on how patients respond to the study treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rhuMAb 2C4 |
Timeline
- Start date
- 2001-11-01
- Primary completion
- 2003-08-01
- Completion
- 2003-08-01
- First posted
- 2001-11-16
- Last updated
- 2015-07-27
- Results posted
- 2015-07-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00027027. Inclusion in this directory is not an endorsement.